Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

This study is currently recruiting participants.
Verified March 2014 by Masonic Cancer Center, University of Minnesota
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00432094
First received: February 5, 2007
Last updated: March 4, 2014
Last verified: March 2014

February 5, 2007
March 4, 2014
December 2006
December 2014   (final data collection date for primary outcome measure)
Overall survival (OS) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.
Probability of overall survival (OS) at 1 year
Complete list of historical versions of study NCT00432094 on ClinicalTrials.gov Archive Site
  • Disease-free survival (DFS) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
  • Engraftment of platelets [ Time Frame: Day 42 and Day 100 ] [ Designated as safety issue: No ]
    Platelet engraftment is defined as 20,000/mm^3 (20 x 10^9/L) for 3 consecutive days unsupported by a platelet transfusion.
  • Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells [ Time Frame: Pre-Transplant ] [ Designated as safety issue: No ]
    Number of patients unable to achieve adequate stem cell mobilization, need to undergo one or tandem transplantation. Stem cell mobilization = A process in which certain drugs are used to cause the movement of stem cells from the bone marrow into the blood. The stem cells can be collected and stored. They may be used later to replace the bone marrow during a stem cell transplant.
  • Engraftment of neutrophils [ Time Frame: Day 42 and Day 100 ] [ Designated as safety issue: No ]
    Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.
  • Probability of disease-free survival (DFS) at 1 year
  • Toxicity rate
  • Probability of engraftment of neutrophils and platelets
  • Numbers of patients unable to adequately mobilize sufficient peripheral blood stem cells (PBSC)
  • Prognostic factors of patients unlikely to mobilize sufficient PBSC
  • Comparison of outcomes of OS and DFS in patients undergoing single vs tandem transplantation
Not Provided
Not Provided
 
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured. Patients who fall into the poor risk category or others who relapse can be successfully salvaged with high dose chemotherapy and autologous stem cell transplant (AuSCT). As in other diseases such as myeloma, sequential high dose chemotherapy and AuSCT may improve overall and disease free survival.

PURPOSE: Because prior investigations in GCT suggest that a subset of high risk or relapsed patients may be cured with sequential cycles of high dose chemotherapy and AuSCT, we propose investigating how well non-cross resistant conditioning regimens work in treating patients with relapsed or high risk GCT.

OBJECTIVES:

Primary

  • Determine overall survival (OS) of patients with germ cell tumors treated with tandem autologous stem cell transplantation with non-cross-resistant conditioning regimens.

Secondary

  • Determine disease-free survival (DFS) of patients treated with this regimen.
  • Determine the toxicity of tandem transplants
  • Determine the time to engraftment of neutrophils and platelets in patients treated for each transplant
  • Determine the number of patients unable to adequately mobilize sufficient peripheral blood stem cells (PBSC) for tandem transplantation.
  • Identify prognostic factors of patients unlikely to mobilize sufficient PBSC for tandem transplantation.
  • Compare OS and DFS of patients undergoing single vs tandem transplantation.

OUTLINE:

  • Peripheral blood stem cell (PBSC) mobilization with filgrastim (G-CSF): Patients receive G-CSF subcutaneously (SC) beginning on day 1 and continuing until stem cell collection is complete. Patients undergo stem cell collection beginning on day 5 of G-CSF administration and continuing for at least 3 collections until the collection goal is met.
  • Second PBSC mobilization with chemotherapy: Patients not meeting the collection goal receive cyclophosphamide IV over 2 hours on day 1 and G-CSF SC beginning on day 4 and continuing until stem cell collection is complete. Patients meeting the collection goal after PBSC mobilization via G-CSF alone or in combination with chemotherapy will undergo tandem autologous transplantation. If collection goal is not met but the patient has collected > or = 2 x 10^6 CD34 cells/kg, a single autologous transplant will be performed.
  • Single stem cell transplantation (SCT): Patients receive paclitaxel IV over 3 hours on day -7 and ifosfamide IV on days -6 to -4. Patients undergo reinfusion of stem cells on day 0. Patients also receive G-CSF SC or IV beginning on day 1 and continuing until blood counts recover.
  • Tandem SCT: Patients receive treatment as in single SCT. Beginning 30-90 days later, patients receive carboplatin IV over 60 minutes and thiotepa IV over 30 minutes on days -6 to -4 and etoposide IV over 60 minutes on days -6 to -3. Patients undergo reinfusion of stem cells on day 0. Patients also receive G-CSF SC or IV beginning on day 5 and continuing until blood counts recover.

After completion of study treatment, patients are followed at 6, 9, and 12 months and then every 6 months for up to 2 years.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Childhood Germ Cell Tumor
  • Ovarian Cancer
  • Teratoma
  • Drug: carboplatin
    Days -6, -5, -4: 500mg/m2^/day intravenously (IV) over 60 minutes
  • Drug: etoposide
    600mg/m^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
    Other Names:
    • VP-16
    • Toposar
  • Drug: ifosfamide
    2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
    Other Names:
    • Mitoxana
    • Ifex
  • Drug: paclitaxel
    225 mg/m^2 intravenous over 3 hours on Day -7.
    Other Name: Taxol
  • Drug: thiotepa
    150mg/m^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
    Other Name: N,N'N'-triethylenethiophosphoramide
  • Procedure: autologous hematopoietic stem cell transplantation
    Peripheral blood stem cell infusion (< 4 x 10^6 CD34+ cells/kg)
    Other Name: PBSC
  • Drug: Mesna
    2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
    Other Name: Uromitexan®
  • Biological: filgrastim
    Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
    Other Name: G-CSF
  • Experimental: 2 Transplants
    Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.
    Interventions:
    • Drug: carboplatin
    • Drug: etoposide
    • Drug: thiotepa
    • Procedure: autologous hematopoietic stem cell transplantation
    • Biological: filgrastim
  • Active Comparator: 1 Transplant
    Patients with Germ cell tumors who receive one transplant only.
    Interventions:
    • Drug: ifosfamide
    • Drug: paclitaxel
    • Procedure: autologous hematopoietic stem cell transplantation
    • Drug: Mesna
    • Biological: filgrastim
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
25
June 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis: Poor Prognosis Non-Seminomas Germ Cell Tumor in ≥ PR1/CR1 or Good or Intermediate Prognosis Seminomas and Non- Seminomas Germ Cell Tumor in ≥ PR1 or ≥ CR2 as defined by the International Germ Cell Cancer Consensus Classification. Patients with increasing tumor markers only (i.e. no imaging evidence of progressive disease) are eligible for transplant.
  • Age: ≥ 10 years and < 70 years of age.
  • Performance status: Karnofsky ≥ 80% (subjects ≥ 16 years of age) Lansky ≥ 80% for subject 10 - 15 years of age
  • Life expectancy: Greater than 8 weeks.
  • Patients must have normal organ function as defined below:

    • Hematologic:

      • Hemoglobin > 8 gm/dL without transfusion and off erythropoietin for 14 days or Aranesp for 21 days
      • White blood cells (WBC) > 2.5 x 10^9/L with an absolute neutrophile count (ANC) > 1.5 x 10^9/L and off G-CSF or GM-CSF for 10 days or Neulasta for 21 days
      • Platelets > 100 x 10^9/L without transfusion and/or a bone marrow cellularity of ≥ 20%
    • Renal: Creatinine ≤ 2.0 mg/dl or creatinine clearance > 50 ml/min.
    • Hepatic: Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase < 5 x upper limit of normal. No history of severe prior or ongoing chronic liver disease.
    • Cardiac: Patients must be free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. LVEF ≥45% by MUGA/ECHO.
    • Pulmonary: Patients must have no significant obstructive airways disease (FEV1 must be ≥ 50% of predicted) and must have acceptable diffusion capacity (corrected DLCO > 50% of predicted).
  • Patients with a history of CNS tumor involvement are eligible if they have completed treatment for CNS disease (radiotherapy or surgery or chemotherapy), have recovered from or stabilization of the side effects associated with the therapy and have no evidence of progressive CNS disease at the time of enrollment.

Exclusion Criteria:

  • Patients with serious uncontrolled infections will not be eligible.
  • Male and female patients of reproductive potential must use an approved contraceptive method if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for the duration of study participation. The drugs used in this study are pregnancy category D - clear evidence of risk in pregnancy.
  • Pregnant and breast feeding women will not be eligible.

Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Additional Eligibility prior to Transplant Two:

  • Total Collection of ≥ 4 x 10^6 CD34 cells/kg prior to transplant one
  • Transplant able to occur between day +30 and day +90 from transplant one
  • Recovery of blood counts as demonstrated by:

    • WBC > 2.5 x 10^9/L with an ANC > 1.5 x 10^9/L and off G-CSF for 3 days
    • Platelets > 50 x 10^9/L without transfusion in the prior 7 days
    • Renal: Creatinine ≤ 2.0 mg/dl or creatinine clearance > 50 ml/min
    • Hepatic: Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase < 5 x upper limit of normal
  • Infection: Patients with serious uncontrolled infections at the time of planned transplant will be excluded
  • Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant. Tumor marker increase alone is not sufficient to diagnose disease progression.
Both
10 Years to 69 Years
No
Contact: Timothy Krepski 612-273-2800 tkrepsk1@fairview.org
United States
 
NCT00432094
2006LS032, UMN-MT2005-21, UMN-0608M90586
Yes
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Not Provided
Principal Investigator: Brian McClune, DO Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP